GlassScriptPhysician profile
Stephanie Ford
NPI 1437266418
$2,550.34
in general payments reported to CMS, 2019-2025
13 companies · $561 in 2025
The $561 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $363 · 2023: $418 · 2024: $1,208 · 2025: $561.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,187.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $713.75 | 2023-2024 | Variax, Gamma, Axsos |
| Tris Pharma INC | $381.18 | 2024-2025 | Dyanavel Xr, Quillichew Er, Quillivant |
| Supernus Pharmaceuticals, INC. | $285.80 | 2023-2025 | Qelbree, Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $228.85 | 2022-2024 | Caplyta |
| Abbvie INC. | $220.98 | 2022-2023 | |
| Collegium Pharmaceutical, INC. | $170.66 | 2025 | Jornay Pm |
| Janssen Pharmaceuticals, INC | $150.00 | 2025 | Spravato |
| Regeneron Healthcare Solutions, INC. | $121.83 | 2024 | Dupixent |
| Axsome Therapeutics, INC. | $109.01 | 2023 | Auvelity |
| Glaxosmithkline, LLC. | $100.78 | 2022 | |
| Organon LLC | $30.54 | 2023 | Nexplanon |
| Ironshore Pharmaceuticals INC. | $21.68 | 2024 | |
| Lundbeck LLC | $15.28 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Ford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.